Results 41 to 50 of about 4,767 (196)

Supplementary Data from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

, 2022
Supplementary Data from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in ...
Victoria A. Jennings (9473021), Barbara da Silva (15129239), Bethany Kuszlewicz (15129227), Karen J. Scott (15129221), Rebecca Auer (3638254), Nicolas Stojkowitz (15129245), Alan Anthoney (458062), Christy Ralph (15129260), Giles J. Toogood (7505084), Darren J. Newton (15129263), Richard G. Vile (14889684), Adel Samson (15129212), Emma Tidswell (6902300), Jennifer Kingston (9119774), Rajiv V. Dave (15129230), Hardev Pandha (3452105), Samantha Turnbull (15129224), Michelle Johnpulle (15129236), Jonathan Carmichael (15129218), Monika Lusky (526654), Adam Peckham-Cooper (15129233), Chris J. Twelves (15129254), Kevin J. Harrington (8292093), Alan A. Melcher (9473024), Emma J. West (15129215), Kaidre Bendjama (15129242), Fiona Errington-Mais (15129257), John Bell (15129251), K.R. Prasad (15129248), Fiona Collinson (15129266)   +29 more
core   +1 more source

Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development [PDF]

Molecular Therapy - Oncolytics, 2021
Vaccinia virus (VV) has emerged as a promising platform for oncolytic virotherapy. Many clinical VV candidates, such as the double-deleted VV, vvDD, are engineered with deletions that enhance viral tumor selectivity based on cellular proliferation rates.
Tiffany Y. Ho, David Mealiea, Lili Okamoto, David F. Stojdl, J. Andrea McCart   +4 more
openaire   +3 more sources

Supplementary Figure from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

, 2022
Supplementary Figure from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in ...
Victoria A. Jennings (9473021), Barbara da Silva (15129239), Bethany Kuszlewicz (15129227), Karen J. Scott (15129221), Rebecca Auer (3638254), Nicolas Stojkowitz (15129245), Alan Anthoney (458062), Christy Ralph (15129260), Giles J. Toogood (7505084), Darren J. Newton (15129263), Richard G. Vile (14889684), Adel Samson (15129212), Emma Tidswell (6902300), Jennifer Kingston (9119774), Rajiv V. Dave (15129230), Hardev Pandha (3452105), Samantha Turnbull (15129224), Michelle Johnpulle (15129236), Jonathan Carmichael (15129218), Monika Lusky (526654), Adam Peckham-Cooper (15129233), Chris J. Twelves (15129254), Kevin J. Harrington (8292093), Alan A. Melcher (9473024), Emma J. West (15129215), Kaidre Bendjama (15129242), Fiona Errington-Mais (15129257), John Bell (15129251), K.R. Prasad (15129248), Fiona Collinson (15129266)   +29 more
core   +1 more source

Oncolytic cancer therapy with a vaccinia virus strain

Oncology Reports, 2018
Oncolytic vaccinia virus is currently undergoing evaluation as a biological anticancer agent in clinical trials. This treatment exploits the lytic nature of a viral infection to eradicate the tumor mass in a cancer cell‑specific manner. So far, various vaccinia strains have been used as backbones in the design of oncolytic agents. However, the efficacy
Lili, Deng, Jun, Fan, Yuedi, Ding, Jue, Zhang, Bin, Zhou, Yi, Zhang, Biao, Huang, Zhigang, Hu   +7 more
openaire   +3 more sources

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

Molecular Therapy: Oncolytics, 2014
Successful cancer control relies on overcoming resistance to cell death and on activation of host antitumor immunity. Oncolytic viruses are particularly attractive in this regard, as they lyse infected tumor cells and trigger robust immune responses ...
Markus Vähä-Koskela, Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Kristian Taipale, Dipongkor Saha, Maiju Merisalo-Soikkeli, Marko Ahonen, Noora Rouvinen-Lagerström, Mari Hirvinen, Ville Veckman, Sampsa Matikainen, Fang Zhao, Päivi Pakarinen, Jarmo Salo, Anna Kanerva, Vincenzo Cerullo, Akseli Hemminki   +16 more
doaj   +1 more source

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans [PDF]

Cancer Research, 2013
Abstract Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specifically infect and express transgenes (hGM-CSF, β-galactosidase) in tumor-associated ...
Caroline J, Breitbach, Rozanne, Arulanandam, Naomi, De Silva, Steve H, Thorne, Richard, Patt, Manijeh, Daneshmand, Anne, Moon, Carolina, Ilkow, James, Burke, Tae-Ho, Hwang, Jeong, Heo, Mong, Cho, Hannah, Chen, Fernando A, Angarita, Christina, Addison, J Andrea, McCart, John C, Bell, David H, Kirn   +17 more
openaire   +2 more sources

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics [PDF]

Journal for ImmunoTherapy of Cancer, 2019
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents.
Zong Sheng Guo, Binfeng Lu, Zongbi Guo, Esther Giehl, Mathilde Feist, Enyong Dai, Weilin Liu, Walter J. Storkus, Yukai He, Zuqiang Liu, David L. Bartlett   +10 more
openaire   +3 more sources

Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function

Molecular Therapy: Oncolytics, 2019
Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables its ...
Motomu Nakatake, Hajime Kurosaki, Nozomi Kuwano, Kosuke Horita, Mai Ito, Hiromichi Kono, Tomotaka Okamura, Kosei Hasegawa, Yasuhiro Yasutomi, Takafumi Nakamura   +9 more
doaj   +1 more source

Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation

Molecular Therapy: Oncolytics, 2021
We have demonstrated that oncolytic vaccinia virus synergizes with doxorubicin (DOX) in inducing immunogenic cell death in platinum-resistant ovarian cancer cells and increases survival in syngeneic and xenograft tumor models.
Anna Mistarz, Matthew Graczyk, Marta Winkler, Prashant K. Singh, Eduardo Cortes, Anthony Miliotto, Song Liu, Mark Long, Li Yan, Aimee Stablewski, Kieran O’Loughlin, Hans Minderman, Kunle Odunsi, Hanna Rokita, A.J. Robert McGray, Emese Zsiros, Danuta Kozbor   +16 more
doaj   +1 more source

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Frontiers in Cellular and Infection Microbiology, 2023
Recent reports have revealed that oncolytic viruses (OVs) play a significant role in cancer therapy. The infection of OVs such as oncolytic vaccinia virus (OVV), vesicular stomatitis virus (VSV), parvovirus, mammalian reovirus (MRV), human adenovirus ...
Yi-Ying Wu, Yi-Ying Wu, Te-Kai Sun, Ming-Shan Chen, Muhammad Munir, Hung-Jen Liu, Hung-Jen Liu, Hung-Jen Liu, Hung-Jen Liu, Hung-Jen Liu   +9 more
doaj   +1 more source